IADR Abstract Archives
Sclerostin Antibody Enhances the Alveolar Bone Regeneration Surrounding Dental Implants
Objectives: Background: Dental implants are an important option for replacing lost teeth. A major clinical goal is to accelerate bone healing times for functional restoration after implant placement. Antibody against Sclerostin (Scl-Ab) has been shown to enhance bone formation and bone fracture repair.
Aim: To investigate the effects of Scl-Ab on bone regeneration and dental implant osseointegration in an experimental alveolar bone defect model.
Methods: one month after maxillary first molar extraction in rats, a “well type” osteotomy was created at the extraction site, and a 1x2 mm dental titanium implant was placed into the osteotomy site. Following the first day of implant placement, Scl-Ab (25 mg/kg) was administrated systemically by twice-weekly SC injections. PBS was injected as a vehicle control. Ten and 14 days after surgery, the maxillae were harvested, fixed by 10% formalin, scanned and analyzed by microCT. After microCT scanning, the maxillae were embedded in resin, sectioned and stained with methylene blue and acid fuchsin for descriptive histology and histomorphometry.
Results: MicroCT analysis demonstrated that bone volume fraction was approximately 2-fold greater in Scl-Ab treatment groups compared to vehicle alone at day 14. Bone fill percentage and bone-implant contact percentage were not different between two groups at day 10 and day 14.
Conclusions: Scl-Ab enhanced bone regeneration around dental implants in alveolar bone defects. This treatment approach offers potential to help accelerate bone healing around dental implant sites placed simultaneously into bony defects. Supported by the Osteology Foundation.
Aim: To investigate the effects of Scl-Ab on bone regeneration and dental implant osseointegration in an experimental alveolar bone defect model.
Methods: one month after maxillary first molar extraction in rats, a “well type” osteotomy was created at the extraction site, and a 1x2 mm dental titanium implant was placed into the osteotomy site. Following the first day of implant placement, Scl-Ab (25 mg/kg) was administrated systemically by twice-weekly SC injections. PBS was injected as a vehicle control. Ten and 14 days after surgery, the maxillae were harvested, fixed by 10% formalin, scanned and analyzed by microCT. After microCT scanning, the maxillae were embedded in resin, sectioned and stained with methylene blue and acid fuchsin for descriptive histology and histomorphometry.
Results: MicroCT analysis demonstrated that bone volume fraction was approximately 2-fold greater in Scl-Ab treatment groups compared to vehicle alone at day 14. Bone fill percentage and bone-implant contact percentage were not different between two groups at day 10 and day 14.
Conclusions: Scl-Ab enhanced bone regeneration around dental implants in alveolar bone defects. This treatment approach offers potential to help accelerate bone healing around dental implant sites placed simultaneously into bony defects. Supported by the Osteology Foundation.